Karolinska Development
1.53 SEK 0%1 investor is following this company
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Revenue
-
EBIT %
-
P/E
76.5
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
KDEV
Daily low / high price
1.5 / 1.57
SEK
Market cap
413.22M SEK
Turnover
340.16K SEK
Volume
222K
Financial calendar
Interim report
2024-08-30
Interim report
2024-11-15
Annual report
2025-02-14
Interim report
2025-04-30
General meeting
2025-05-15
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
invoX Pharma Ltd | 47.7 % | 43.9 % |
Worldwide International Investments Ltd | 10.4 % | 9.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
Karolinska Developments portföljbolag Umecrine Cognition säkrar finansiering för den fortsatta kliniska utvecklingen av golexanolon
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools